Shots:

• The approval is based on trial assessing Riabni (375 mg/m2- IV) vs Rituxan once weekly for 4wks. followed by dosing @12wks. & 20wks. in 256 patients in a ratio (1:1) with grade 1- 2- or 3a follicular B-cell NHL & low tumor burden
• The WAC of Riabni will be 23.7% lower than the Rituxan in the US and will be available at a WAC of $716.80/ 100mg and $3-584.00/ 500mg single-dose vial
• Riabni is a biosimilar to Rituxan- approved for the treatment of NHL- CLL- GPA- MPA and ill be made available in the US in Jan 2021

 ­ Ref: PRNewswire | Image: Adweek